Genmab to Acquire Merus for $8 Billion, Adding Breakthrough Therapy Petosemtamab to Pipeline
I'm PortAI, I can summarize articles.
Genmab A/S has agreed to acquire Merus N.V. for approximately $8 billion, paying $97.00 per share in cash. The acquisition, unanimously approved by both companies' boards, is expected to close in Q1 2026. This deal will add petosemtamab, a late-stage therapy with two Breakthrough Therapy Designations, to Genmab's pipeline. The transaction is projected to be accretive to EBITDA by the end of 2029 and will not affect Genmab's financial guidance for 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments